Carisma Therapeutics INC

Carisma Therapeutics Inc. announced its voluntary delisting from Nasdaq, executive and board changes, and plans to terminate SEC reporting obligations as it proceeds with wind-down activities.

Carisma Therapeutics Inc. announced the termination of its CEO and CSO, along with multiple board resignations, as it pursues an orderly wind-down of operations.

Carisma Therapeutics Inc. received a delisting notice from Nasdaq, with trading to cease on October 13, 2025, and plans to move to the OTCID market tier while pursuing an orderly wind-down.

Carisma Therapeutics Inc. terminated its merger agreement with OrthoCellix due to failed financing and amended its collaboration with Moderna for a one-time payment.

Carisma Therapeutics Inc. announced a $5 million private placement with Ocugen, an extension for Nasdaq listing compliance, and an amended employment agreement for its CEO, all tied to its pending merger with OrthoCellix.

Carisma Therapeutics Inc. stockholders approved a reverse stock split proposal at a Special Meeting, granting the Board discretion on the ratio and timing, alongside discussions of a proposed merger with OrthoCellix Inc.

Carisma Therapeutics Inc. reported Q3 2025 results, confirming its strategic shift to an orderly wind-down of operations after a failed merger and Nasdaq delisting.

Carisma Therapeutics reports Q2 2025 results, detailing a planned merger with OrthoCellix, significant operational wind-down, and ongoing Nasdaq compliance challenges.

Carisma Therapeutics is reducing operations and exploring strategic alternatives, including a potential wind-down, due to insufficient cash resources.

Carisma Therapeutics reported a net loss of $42.8 million for the nine months ended September 30, 2024, and anticipates sufficient cash to sustain operations into the third quarter of 2025.

Carisma Therapeutics announced its Q2 2024 financial results, highlighting a strategic shift to prioritize its lead product candidate, CT-0525, and a revised operating plan to extend its cash runway.

Carisma Therapeutics announced its first quarter 2024 results, highlighting a strategic shift to prioritize its CT-0525 program and reduce operating expenses.

Carisma Therapeutics files an amendment to its 2024 Annual Report on Form 10-K, including detailed information on directors, executive compensation, corporate governance, and related matters omitted from the original filing.

Carisma Therapeutics halts research and development, explores strategic alternatives including asset sales, and prepares for a potential wind down to preserve cash.

Carisma Therapeutics Inc. is focusing its clinical development on CT-0525, a novel CAR-Monocyte therapy, while suspending new patient enrollment in its CT-0508 trial and pausing CT-1119 development.

Carisma Therapeutics' Chief Scientific Officer, Michael Klichinsky, exercised stock options and subsequently sold 56,982 shares of common stock.

Carisma Therapeutics' Chief Scientific Officer, Michael Klichinsky, sold all of his direct common stock holdings over three days in early October 2025, pursuant to a Rule 10b5-1 plan.

Carisma Therapeutics Inc. is progressing its merger with OrthoCellix, securing a $5.0 million investment from Ocugen and extending its Nasdaq compliance deadline.

Carisma Therapeutics Inc. stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50, granting the Board discretion on implementation.

Carisma Therapeutics Inc. received an additional delisting notice from Nasdaq for failing to meet the minimum bid price requirement and plans a reverse stock split to regain compliance while also pursuing a merger with OrthoCellix, Inc.

Carisma Therapeutics Inc. and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., have entered into a definitive merger agreement, with OrthoCellix becoming a wholly-owned subsidiary of Carisma, alongside a proposed concurrent financing.

Carisma Therapeutics Inc. seeks stockholder approval for a reverse stock split to meet Nasdaq listing requirements and facilitate its merger with OrthoCellix.

Carisma Therapeutics Inc. is holding a special stockholder meeting on August 5, 2025, to vote on a reverse stock split aimed at regaining Nasdaq compliance and meeting conditions for its proposed merger with OrthoCellix, Inc.

Carisma Therapeutics announces its 2024 annual meeting of stockholders to be held virtually on June 13, 2024, featuring proposals for director elections, executive compensation advisory vote, and ratification of KPMG LLP as the independent auditor.

HealthCap VII, L.P. and HealthCap VII GP LLC have fully divested their beneficial ownership in Carisma Therapeutics Inc., ceasing to be a greater than five percent holder as of September 2, 2025.

HealthCap VII, L.P. and its general partner have significantly reduced their beneficial ownership in Carisma Therapeutics Inc., falling below the 5% threshold.

HealthCap VII, L.P. and HealthCap VII GP LLC have reduced their beneficial ownership in Carisma Therapeutics Inc. to 6.5% through a series of stock sales.

AbbVie Biotechnology Ltd. has filed an amended Schedule 13G, disclosing its beneficial ownership in Carisma Therapeutics Inc. has fallen to 4.4% of outstanding common stock.